TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02894502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The intervention will consist of a brief session of motivational interviewing (MI) performed by a trained nurse. During MI, the interventionist will address one or two aspects of self-care that the participants want to address. After this first intervention, the same interventionist will contact the participant by telephone to improve the first intervention and provide further support as needed. These telephone contact will be done three times at two week intervals following the first intervention (for a total of two months). Patients and caregivers that receive the intervention also will be given informational material on HF management that is consistent with international guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The intervention will consist of a brief session of motivational interviewing (MI) performed by a trained nurse. During MI, the interventionist will address one or two aspects of self-care that the participants want to address. After this first intervention, the same interventionist will contact the participant by telephone to improve the first intervention and provide further support as needed. These telephone contact will be done three times at two week intervals following the first intervention (for a total of two months). Patients and caregivers that receive the intervention also will be given informational material on HF management that is consistent with international guidelines.
Study: NCT00472680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction, high protein
Description: Weight loss with higher protein (35%) intake

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction; normal protein
Description: Weight loss with normal level of protein (18%) intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
Study: NCT04316403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: This application was made before the onset of canine retraction in one side of the mouth
Study: NCT02494063

Intervention type: PROCEDURE
Intervention: Sentinel lymph node biopsy
Description: Bilateral sentinel lymph node biopsy, pathologic ultrastaging
Study: NCT03110588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACE with Cabazitaxel (15 mg/m2)
Description: Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACE with Cabazitaxel (20 mg/m2)
Description: Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.
Study: NCT03484715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: A physical activity programme will be developed by the researcher for each participant. Integral to each physical activity programme will be a walking component (i.e. structured and gradual increases in daily walking time) and sit-to-stand exercises (i.e. a specified number of repeated rises from a chair). The rest of the physical activity programme will be tailored around each participant's specific functional goal and will be based on repeating particular functional activities. This programme will take place on 3 days per week in month 1, 4 days per week in month 2 and 3, and 5 days a week in month 4.
Study: NCT03168815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula or Low Flow Nasal Cannula
Description: HFNC vs LFNC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula or Low Flow Nasal Cannula
Description: HFNC vs LFNC
Study: NCT02211261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: subcutaneous, single dose 0.3 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous normal saline single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous, single dose 1.0 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous normal saline single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous single dose 3 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous normal saline single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous single dose 6 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous normal saline single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Intravenous infusion single dose 1 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion normal saline single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous injection multiple dose TBD mg (Days TBD)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection normal saline multiple dose (Days TBD)
Study: NCT05179616

Intervention type: PROCEDURE
Intervention: Transcatheter edge-to-edge tricuspid valve repair
Description: Percutaneous edge to edge repair of tricuspid valve using the TriClip system
Study: NCT02494063

Intervention type: PROCEDURE
Intervention: At least unilateral systematic pelvic lymph node dissection
Study: NCT02553252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga Trauma Relief Program (SKY)
Description: Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
Study: NCT04352972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele-monitored home exercise program
Description: Tele-monitoring home exercise program used in the home with monitoring by physiotherapists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital-based rehabilitation program
Description: Participants will receive a maximum of 8 sessions over 10 weeks with the option of two additional sessions. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion. Participants will also receive a set of home exercises and they will be instructed to exercise on days when not attending rehabilitation.
Study: NCT02265588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
Study: NCT04958395

Intervention type: DIAGNOSTIC_TEST
Intervention: FFR and d-FFR
Description: Measure FFR and d-FFR
Study: NCT05197660

Intervention type: PROCEDURE
Intervention: surgical procedures
Description: number of hospital stays

Intervention type: PROCEDURE
Intervention: surgical procedures
Description: number of hospital stays

Intervention type: PROCEDURE
Intervention: surgical procedures
Description: number of hospital stays

Intervention type: PROCEDURE
Intervention: surgical procedures
Description: number of hospital stays

Intervention type: PROCEDURE
Intervention: surgical procedures
Description: number of hospital stays
Study: NCT01873612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxic ventilatory response

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxic ventilatory response

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercapnic ventilatory response

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercapnic ventilatory response
Study: NCT04294056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
Study: NCT02870933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transepicardial with Transseptal CD 133+ Implantation
Description: Transepicardial with Transseptal CD 133+ Implantation
Study: NCT03505840

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound with Doppler and 3D technology
Description: ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound with Doppler and 3D technology
Description: ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology
Study: NCT03196492

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02809040

Intervention type: OTHER
Intervention: Electrocardiogram/Echocardiography
Description: Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.~Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart.

Intervention type: OTHER
Intervention: Electrocardiogram/Echocardiography
Description: Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.~Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart.

Intervention type: OTHER
Intervention: Electrocardiogram/Echocardiography
Description: Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.~Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart.

Intervention type: OTHER
Intervention: Portable digital auscultation
Description: Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.~Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation

Intervention type: OTHER
Intervention: Portable digital auscultation
Description: Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.~Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation

Intervention type: OTHER
Intervention: Portable digital auscultation
Description: Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.~Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation
Study: NCT00601042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish snus (smokeless tobacco)
Description: Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Onico
Description: Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
Study: NCT00511394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% Human Albumin
Description: Infusion of 100 mL of 20% Albumin over 3 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Infusion of 100 mL of Normal Saline
Study: NCT00646854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab
Description: Cyclophosphamide 750 mg/m2 i.v. on day 1 Hydroxydaunorubicin 50 mg/m2 i.v. on day 1 Vincristin 1 mg/m2 i.v. day 1 (max. 2mg) Prednisone 50 mg/m2 p.o. day 1 to 5 Alemtuzumab 30 mg s.c.on day 1 of CHOP-14 cycles 1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
Description: 6 cycles of CHOP every 2 weeks
Study: NCT01956344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Group cognitive-behavioral therapy for hoarding disorder, 16 weeks
Study: NCT01332799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol or placebo
Description: Daily active drug (allopurinol administered orally) administered orally for 3 years.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill administered orally for 3 years.
Study: NCT05873907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as SC injection
Study: NCT03223168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hayek RTX ventilator
Description: Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
Study: NCT00575341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone
Description: 25 mg DHEA, oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, oral, once daily
Study: NCT00118456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEE788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEE788
Study: NCT03141294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reformative dilation technique
Description: reformative dilation technique was used when operating tracheostomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: reformative dilation technique
Description: reformative dilation technique was used when operating tracheostomy
Study: NCT04229732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearMateTM
Description: Passive isocapnic hyperventilation breathing circuit.
Study: NCT04193514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The intervention is a 7-day self-guided acceptance-based intervention using a published Acceptance and Commitment Therapy self-help work book. This therapy is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of depression, anxiety and/or stress. The therapy includes two components: (a) educating patients about the exacerbation of stress and negative affect through rigid attempts at experiential avoidance, and (b) introducing acceptance and the willingness to experience pregnancy-related sensations and cognitions as an alternative to experiential control, through the practice of intentional and non-judgmental paying attention to one's thoughts, feelings, images and bodily sensations (including aversive symptoms) and learning to see thoughts as an ongoing process distinct from self rather than merely an event with literal meaning.
Study: NCT05925543

Intervention type: PROCEDURE
Intervention: Kasai portoenterostomy operation.
Description: Kasai portoenterostomy operation for biliary atresia patients.
Study: NCT02224885

Intervention type: DEVICE
Group type: OTHER
Intervention: CT-guided percutaneous biopsy or ablation
Description: Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung
Study: NCT00377390

Intervention type: BIOLOGICAL
Intervention: Omalizumab
Description: Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).

Intervention type: BIOLOGICAL
Intervention: Omalizumab
Description: Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
Study: NCT05354648

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxic-hyperoxic preconditioning
Description: Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia. HHP was carried out as follows: breathing with a hypoxic gas mixture for 10 min with the development of hypoxemia, then breathing with a hyperoxic gas mixture for 30 minutes, then a period of breathing with atmospheric air (normoxia and normocapnia) until the cardio-pulmonary bypass is connected.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia until the cardio-pulmonary bypass is connected.
Study: NCT04016532

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Personalized dietary management at home
Description: Personalized dietary management at home to improve nutritional status.~* Four (J7, J30, J60 and J90 for non-undernutrition patients) or five Home visits (J7, J15, J30 and J90 for undernutrition patients or at risk of undernutrition) by professional dietitians from Saveurs \& Vie over a period of 3 months after discharge from the hospital: personalized dietary advice and recipe sheet.~* There will be no change in medical prescriptions

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Personalized dietary management at home
Description: Personalized dietary management at home to improve nutritional status.~* Four (J7, J30, J60 and J90 for non-undernutrition patients) or five Home visits (J7, J15, J30 and J90 for undernutrition patients or at risk of undernutrition) by professional dietitians from Saveurs \& Vie over a period of 3 months after discharge from the hospital: personalized dietary advice and recipe sheet.~* There will be no change in medical prescriptions
Study: NCT03663478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 2 x 30 ml ropivacaine 0,2% and an elastomere pump with 200 ml ropivacaine 0,2%, infusion rate 8 ml/hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 x 30 mL isotonic saline and an elastomere pump with 200 ml isotonic saline, infusion rate 8 ml/hour
Study: NCT01257009

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: 6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: 6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity